Dengvaxia® (dengue tetravalent vaccine, live) – New drug approval
May 1, 2019 - The FDA announced the approval of Sanofi Pasteur’s Dengvaxia (dengue tetravalent vaccine, live), for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. Dengvaxia is approved for use in individuals 9 through 16 years of age with laboratory confirmed previous dengue infection and living in endemic areas.
Top